TUS-PHARMA announced that it expects the net profit attributable to shareholders of the listed company for the period from January 1, 2025, to June 30, 2025, to be a loss of 19 million to 15 million yuan, compared to a loss of 23.3946 million yuan in the same period last year; the net profit after deducting non-recurring gains and losses is expected to be a loss of 25 million to 20 million yuan, compared to a loss of 24.389 million yuan in the same period last year; the basic earnings per share is expected to be a loss of 0.0793 yuan/share to 0.0626 yuan/share, compared to a loss of 0.0977 yuan/share in the same period last year. The company's total operating revenue has declined in the past two years due to factors such as market environment, and the prices of some raw and auxiliary materials have risen, leading to a decrease in overall gross profit margin and profitability
